Comparative Pharmacology
Head-to-head clinical analysis: OXYTOCIN 20 USP UNITS IN DEXTROSE 5 versus PITOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTOCIN 20 USP UNITS IN DEXTROSE 5 versus PITOCIN.
OXYTOCIN 20 USP UNITS IN DEXTROSE 5% vs PITOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytocin is a nonapeptide hormone that acts on oxytocin receptors (OXTR) in uterine myometrium and mammary gland epithelium, leading to Gq/11-coupled phospholipase C activation, increasing intracellular Ca2+ and promoting uterine smooth muscle contractions. It also stimulates milk ejection by contracting myoepithelial cells.
Oxytocin receptor agonist; stimulates uterine smooth muscle contractions and myoepithelial cell contraction in the mammary gland.
Initial infusion at 0.5-2 mU/min, increased by 1-2 mU/min every 15-30 min until desired uterine activity, then taper. Maximum dose typically 20 mU/min.
IV infusion: 0.5-2 mU/min, increase by 1-2 mU/min every 15-60 minutes until contractions are established; maximum 20 mU/min.
None Documented
None Documented
Terminal elimination half-life: 1–6 minutes (IV), with a slower second phase of 12–20 minutes. Clinical context: Rapid clearance necessitates continuous IV infusion for sustained uterotonic effect.
Terminal elimination half-life is 3-5 minutes (plasma) with a terminal half-life of 1-6 minutes for exogenously administered oxytocin; clinical effects persist 20-30 minutes due to receptor binding.
Primarily renal (>99% as intact peptide, small amount as metabolites). Biliary/fecal excretion negligible.
Primarily renal: 90-95% of the dose is excreted in urine as intact peptide and metabolites; <1% excreted in feces via bile.
Category C
Category C
Oxytocic
Oxytocic